PharmExec Blog
Follow Us
RSS
Bookstore
Category Archives: Guest Blog
England's Cancer Drug Fund: An Acid Test for Value Based Pricing
By Leela Barham.
England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011. The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view. Companies can’t circumvent NICE though; if a company was invited to submit to [...]
Also posted in Europe, Global, Op-Ed, pricing Tagged cancer drug fund, England, NHS, NICE, UK, value-based pricing Leave a comment
"Series A Crunch"? Some Suggestions
Recently, there has been an uptick in newsflow around the “series A crunch”/ “the valley of death” in regards to financing. Because of who we are (a firm that connects investors with private equity investments); we at Poliwogg see a lot of the “crunched” and “valley-dwellers.” We have some good news. The good news is [...]
"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure
“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler.
Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an escalating [...]
Also posted in Op-Ed, Regulatory, Safety, Strategy, healthcare, pricing Tagged drug safety, Obamacare, regulatory affairs, Sunshine Act, transparency 1 Comment
Does India's Glivec Decision Make April Fools of Us All?
By Helen Disney, Pugatch Consilium.
On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual property [...]
Budget Cutters Propose Big Hits on Pharma